| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 1, June 22（Sun.）
Room P (Maesato East, Foyer, Ocean Wing)
- 1P-PM-20
Sequential plasma metabolome and proteome analyses to develop a novel monitoring strategy for patients with epithelial ovarian cancer
(1INGEM, Tohoku Univ., 2ToMMo, Tohoku Univ., 3Grad. Sch. Med., Tohoku Univ.)
oEiji Hishinuma1,2, Shogo Shigeta3, Naomi Matsukawa2, Yasunobu Okamura1,2, Ikuko Motoike2, Kengo Kinoshita1,2, Seizo Koshiba1,2, Muneaki Shimada1,2,3
Epithelial ovarian cancer (EOC) is diagnosed at an advanced stage and its prognosis remains poor although new treatment options. Therefore, more accurate clinical biomarkers are needed to establish appropriate treatment choices. With advances in omics technology provide potential new biomarkers, to overcome the current limitations in therapeutic monitoring by measuring CA125 levels. The current study explored the potential of plasma metabolomic and proteomic analyses as novel monitoring methods for the patients with EOC. Seven patients diagnosed with advanced EOC, who had completed primary multidisciplinary treatment were enrolled. Plasma was sequentially collected for CA125 measurements or before CT scans for disease monitoring. Comprehensive plasma metabolome and proteome analyses was performed using liquid-chromatography mass spectrometry. Of seven patients, six experienced disease recurrence or progression. Ten and four metabolome indicators were highly and weakly associated with resistance to chemotherapeutic treatment. Thirty-seven and nine proteins displayed high and low levels associated with chemotherapeutic resistance. The fluctuation of the several metabolome pathway and protein concentrations was confirmed to correspond to the clinical course of each patient. This pilot study clarified the potential of the comprehensive assessment of metabolome and proteome analysis as a useful tool for developing novel monitoring biomarkers for patients with recurrent EOC.